Skip to main content
Premium Trial:

Request an Annual Quote

BioGx Gets CE Marking for Six Meningitis, Antibiotic Resistance Tests

NEW YORK (GenomeWeb) – BioGx announced today that it has received CE marking for six tests for various meningitis infections and antibiotic-resistant organisms.

The tests are designed to run on Becton Dickinson's PCR-based BD Max platform. The meningitis tests cover viral meningitis based on DNA from HSV-1, HSV-2, and VZV; bacterial meningitis based on DNA from Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae; and bacterial meningitis ELGBS based on DNA from Escherichia coliListeria spp., and Group B Streptococcus.

The antibiotic resistance tests include ones for carbapenem resistance in organisms with the resistance genes KPC, NDM-1, and OXA-48; carbapenem and colistin resistance in organisms with the resistance genes VIM, GES, and mcr-1; and vancomycin resistance in organisms with the resistance genes vanA, vanB, vanC1, and vanC2/3.

Birmingham, Alabama-based BioGx now has 11 CE-marked tests that run on the BD Max system — including ones for influenza A, influenza B, respiratory syncytial virus, mycoplasma/ureaplasma genital infections, Pneumocystis jirovecii infection, tuberculosis, and Bordetella infection — and expects to receive CE marking on an additional 10 before the end of the year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.